HIV-1 p17 Gag (77–85) – HLA-A*02:01 complex (Gag77-85/HLA-A*02:01 or SL9/HLA-A*02:01)

The HIV-1 p17 Gag (77–85) – HLA-A*02:01 complex is formed when the immunodominant peptide SLYNTVATL, derived from the HIV-1 p17 matrix protein, is presented by the HLA-A*02:01 molecule, a common human MHC class I allele[2][3]. This peptide-HLA complex is a primary target for CD8+ cytotoxic T lymphocytes during HIV infection, with strong associations between CTL responses to this epitope and viral control. It is used as a prototypical model for vaccine immunogen design and immune monitoring in HIV research. Additionally, similar peptide-HLA complexes are being explored as targets for novel immunotherapies, such as bispecific T cell receptor (bsTCR) therapeutics and engineered T cells[4]. HIV-1 Gag77–85/HLA-A*02:01 is not a receptor or enzyme, but a peptide-bound MHC class I complex, representing an important immunotherapeutic and diagnostic target[2][3][4].

Other names

Gag77–85/HLA-A2SLYNTVATL/HLA-A*02:01SL9/HLA-A2HIV-1 p17 Gag epitope (77–85) – HLA-A2

Recognition by T cell receptors on cytotoxic T lymphocytes, mediating targeted killing of HIV-infected cells. Used in vaccine or adoptive T-cell therapy approaches to stimulate an HIV-specific immune response.